Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.33 Average PT from Brokerages

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have earned a consensus recommendation of “Moderate Buy” from the eight analysts that are covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $56.33.

Several equities research analysts recently commented on AGIO shares. Scotiabank upped their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research report on Monday, December 9th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Royal Bank of Canada boosted their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Leerink Partnrs cut shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Finally, StockNews.com upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 9th.

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the sale, the insider now directly owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.93% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of AGIO. Nordea Investment Management AB lifted its stake in Agios Pharmaceuticals by 3.6% during the 4th quarter. Nordea Investment Management AB now owns 220,569 shares of the biopharmaceutical company’s stock valued at $7,191,000 after acquiring an additional 7,593 shares in the last quarter. Exome Asset Management LLC purchased a new stake in shares of Agios Pharmaceuticals in the third quarter valued at about $2,941,000. Franklin Resources Inc. bought a new position in shares of Agios Pharmaceuticals during the third quarter valued at about $1,499,000. Geode Capital Management LLC grew its position in Agios Pharmaceuticals by 0.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock worth $60,326,000 after purchasing an additional 6,101 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. increased its stake in Agios Pharmaceuticals by 19.7% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 1,044,154 shares of the biopharmaceutical company’s stock valued at $46,392,000 after buying an additional 172,180 shares during the last quarter.

Agios Pharmaceuticals Trading Down 4.1 %

Shares of AGIO opened at $34.42 on Friday. The firm’s fifty day simple moving average is $46.56 and its two-hundred day simple moving average is $45.43. Agios Pharmaceuticals has a 12 month low of $20.96 and a 12 month high of $62.58. The stock has a market capitalization of $1.96 billion, a P/E ratio of 3.03 and a beta of 0.87.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.